Comparative efficacy and safety of combination therapies for advanced melanoma: a network meta-analysis

BACKGROUND: Currently, the major treatment modalities of advanced melanoma are immune check point and mitogen-activated protein kinase (MAPK) pathway inhibitors. As lacking head-to-head randomizedcontrolled trials (RCTs) comparing immune check point and MAPK pathway inhibitors, we evaluated the effi...

Descripción completa

Detalles Bibliográficos
Autores principales: An, Qing, Liu, Zhihao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327485/
https://www.ncbi.nlm.nih.gov/pubmed/30626368
http://dx.doi.org/10.1186/s12885-018-5259-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327485/
https://www.ncbi.nlm.nih.gov/pubmed/30626368
http://dx.doi.org/10.1186/s12885-018-5259-8

Ejemplares similares